CLDN18.2 immunohistochemistry
A staining test to assess CLDN18.2 expression in stomach cancer.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Assess the percentage and intensity of CLDN18.2 expression.
- Becomes the basis for discussing specific antibody therapy.
Informs decisions
- Compliance with clinical trial and therapy criteria regarding CLDN18.2.
How the test is done
Anti-CLDN18.2 antibody staining of tumor tissue.
- Sample type
- Block tumor tissue
- Estimated result time
- Generally one to two weeks.
Limitations
- Assessment thresholds are still evolving and may vary between facilities.
- Reporting needs to state percentage and intensity, not just positive or negative.
Related
Cancer types
Markers tested
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Stomach Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- CLDN18.2
Biomarker
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Complete pathway
CLDN18.2 in stomach cancer
A CLDN18.2 result is positive. What does it mean and what is worth discussing with the medical team?
- CLDN18.2 markerStarting point: what this marker shows and what it does not decide by itself.
- CLDN18.2 positiveWhat a positive result means under the pathology testing threshold.
- CLDN18.2 IHCA common testing method, including on stored tissue blocks.
- After chemotherapy stops workingThe decision situation when first-line therapy no longer controls the disease.
- ZolbetuximabAn anti-CLDN18.2 therapy approved in several countries and given with chemotherapy.
- Positive CLDN18.2 result guideMeaning of the result, approved options versus investigational ones, and questions for the doctor.
A structured summary so IHC results and treatment history are readable.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.